IMRX vs. BOLT, RPID, RMTI, CARA, LEXX, OCUP, UNCY, NBRV, XLO, and APLM
Should you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Bolt Biotherapeutics (BOLT), Rapid Micro Biosystems (RPID), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Lexaria Bioscience (LEXX), Ocuphire Pharma (OCUP), Unicycive Therapeutics (UNCY), Nabriva Therapeutics (NBRV), Xilio Therapeutics (XLO), and Apollomics (APLM). These companies are all part of the "medical" sector.
Immuneering (NASDAQ:IMRX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
Immuneering has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.
67.7% of Immuneering shares are owned by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. 25.0% of Immuneering shares are owned by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Immuneering had 6 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 8 mentions for Immuneering and 2 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of -0.01 beat Immuneering's score of -0.14 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.
Bolt Biotherapeutics received 56 more outperform votes than Immuneering when rated by MarketBeat users. Likewise, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 61.54% of users gave Immuneering an outperform vote.
Immuneering has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -878.58%. Bolt Biotherapeutics' return on equity of -51.18% beat Immuneering's return on equity.
Immuneering presently has a consensus price target of $13.50, indicating a potential upside of 728.22%. Bolt Biotherapeutics has a consensus price target of $7.00, indicating a potential upside of 530.63%. Given Immuneering's higher possible upside, equities analysts clearly believe Immuneering is more favorable than Bolt Biotherapeutics.
Immuneering has higher earnings, but lower revenue than Bolt Biotherapeutics. Immuneering is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Bolt Biotherapeutics beats Immuneering on 12 of the 18 factors compared between the two stocks.
Get Immuneering News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immuneering Competitors List
Related Companies and Tools
